

IB 230035

Description

IB 230035 cells were isolated from the nervous tissue of a patient with Glioblastoma Multiforme. These patient derived cells (PDC) can be used in cancer, immuno-oncology, and toxicology research.

Organism:	<i>Homo sapien</i> , human	Disease Type:	Glioblastoma Multiforme
Patient Age:	Unknown	Cancer Cell Type:	Glial Cells
Patient Sex:	Unknown	Cell Morphology:	Mixed - Adherent (epithelial-like), suspension and spheroid
Tissue of Origin:	Nerve	Applications:	2D and 3D cell culture

Growth Characteristics and Images

Optimal Seeding Density:	8×10^4 cells/cm ²
Doubling Rate:	~ 28 hours
Expected Viability:	>95%
Average Diameter:	16.4 μ m




Figure 1: Representative brightfield microscope images of IB 230035 taken at 10X magnification.

Model Response to Standard of Care Chemotherapeutics

Table 4: IC₅₀ values of 9 standard of care chemotherapeutic agents for IB 230035 over 3 incubation periods.

Each IC₅₀ value represents an average of 2 biological replicates.

COMPOUND	IC ₅₀ (DAY 3) [M]	IC ₅₀ (DAY 5) [M]	IC ₅₀ (DAY 7) [M]
CARMUSTINE	2.116E-05	6.718E-06	5.918E-06
TEMOZOLOMIDE	ND (>)	ND (>)	6.570E-06
PROCARBAZINE-HCL	ND (>)	1.457E-04	6.988E-05
5-FLUOROURACIL	ND (>)	1.056E-04	1.416E-05
LETROZOLE	ND (>)	6.340E-05	ND (>)
CISPLATIN	3.109E-06	1.892E-06	6.116E-07
TAMOXIFEN	3.379E-06	3.670E-06	4.040E-08
GEMCITABINE	ND (<)	2.763E-08	1.435E-08
PACLITAXEL	3.090E-08	1.953E-08	9.206E-09

ND – Not determined (due to incomplete curve generation at the concentration range tested).

(>) IC₅₀ above tested concentration range (<) IC₅₀ below tested concentration range

Intended Use

This product is intended for laboratory research use only. It is not intended for therapeutic use, consumption, or diagnostic testing in humans or animals.

Revision

This information on this document was last updated on 2024-07-30

Contact information

Inaphaea Biolabs Ltd
Medicity, D6 Thane Road,
Nottingham,
NG90 6BH.
Contact number: 0115 784 0026
Email: info@inaphaea.com